Autopsy report · NCT00184210

Magnetic Resonance (MR) Spectroscopy of Breast Cancer Tissue

“the actual primary goal - establishment of an approved tissue biobank - was reached. 1000 tissue samples were collected. No motivation at this time for continuation as originally planned”

The sponsor’s own words in the registry.

Life of this trial

• Registered 5 years 8 months after it had already started.
• Ran for about 20 years 11 months before it stopped.
• 1,000 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Sponsor

Norwegian University of Science and Technology

Sponsor type

University, hospital or other

Conditions

Breast Neoplasms

Participants

1,000

Sites

1

Countries

Norway

Trials that died the same way

• Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib
  “The study was terminated early due to slow enrollment and limited numbers of viable tissue samples.” (56% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.